How much funding has Alpha-9 Oncology raised?

Alpha-9 Oncology has raised $250.1M in total funding, most recently a Series C round.

Who are Alpha-9 Oncology's investors?

Alpha-9 Oncology's investors include Lightspeed VP, Ascenta Capital, Nextech Invest, General Catalyst, Andreessen Horowitz, Frazier Life Sciences.

When was Alpha-9 Oncology founded?

Alpha-9 Oncology was founded in 2019.

Where is Alpha-9 Oncology headquartered?

Alpha-9 Oncology is headquartered in Vancouver, Canada.

What industry is Alpha-9 Oncology in?

Alpha-9 Oncology operates in Life Sciences, Biotech, Healthcare.

Alpha-9 Oncology

Harnessing the power of radiopharmaceuticals

Vancouver, Canada · Founded 2019 · $250.1M raised

Life Sciences

Biotech

Healthcare

Headquarters: Vancouver
Founded: 2019
Business Model: B2B
Website: a9oncology.com

Total Funding: $250.1M
Last Round: $175.0M Series COct 2024
Rounds: 3

About

Alpha-9 Oncology is a clinical-stage radiopharmaceutical company advancing a distinctive portfolio of bespoke, targeted molecules to treat cancer cells with unparalleled precision. The company employs an iterative process to optimize each part of the molecule — binder, linker, chelator, and radioisotope — supported by state-of-the-art infrastructure and in-house formulation expertise. Alpha-9 is backed by top-tier investors with Phase 1 studies underway, including A9-3408, an Actinium-225-based radiotherapeutic. Headquartered in Vancouver, BC with a U.S. office in Boston, MA.

Summary

Alpha-9 Oncology is a Life Sciences company based in Vancouver, Canada, founded in 2019. It has raised $250.1M in total across 3 rounds, most recently a $175.0M Series C round in Oct 2024. Investors include Lightspeed VP, Ascenta Capital and Nextech Invest.